Completed Trials

AHCC08

AHCC 08	Hepatocellular Carcinoma Registry in Asia (INSIGHT): Insight into Real World Practice of Management of HCC in Asia-Pacific (NCT03233360)
Status	Completed recruitment of 2533 participants in December 2019. Preliminary results presented at ASCO 2018, ILCA (2018), ASCO GI (2019), APPLE (2019), EWALT (2022) and APASL (2022). Publication in progress
Contributing Principal Investigators and Centres	Singapore Pierce Chow (National Cancer Centre), Dan Yock Young (National University Hospital), Brian Goh (Singapore General Hospital) Australia Edmund Tse (Royal Adelaide Hospital), Prof Simone Strasser (Royal Prince Alfred Hospital) China Li Lequn (Guangxi Medical University Cancer Center), Jiangtao Li (Second Affiliated Hospital Zhejiang University School of Medicine), Fan Jia (Zhongshan Hospital, Fudan University), Zhu Xu (Beijing Cancer Hospital), Yuxian Bai (Harbin Medical University Cancer Hospital), Qin Shu-Kui (Nanjing Bayi Hospital) Hong Kong Prof Thomas Yau (Queen Mary Hospital) Japan Masatoshi Kudo (Kindai University Hospital), Junji Furuse (Kyorin University School of Medicine), Kazuaki Shimada (National Cancer Centre), Kiyoshi Hasegawa, (University of Tokyo), Nobuyuki Takemura (National Center of Global Health and Medicine) New Zealand Adam Bartlett (Auckland City Hospital) South Korea Hyun-Ki Yoon (Asan Medical Centre), Kim Yun-Hwan (Korea University Anam Hospital), Joon-Hyeok Lee (Samsung Medical), Ho-Seong Han (Seoul National University Hospital), Yang Jin-Mo (St Vincents Hospital), Choi Jong-Young (St. Mary’s Hospital), Hee-Jung Wang (Ajou University Hospital), Do-Young Kim (Severance Hospital, Yonsei University College of Medicine) Taiwan Peng-Cheng Yuan (China Medical University Hospital), Yee Chao (Taipei Veterans General Hospital), Tsung-Hui Hu (KS-Chang Gung Memorial Hospital), Pin-Nan Cheng (National Cheng Kung University Hospital), Chien-Hung Chen (National Taiwan University Hospital) Thailand Rawisak Chanwat (National Cancer Institute), Supot Ninanong (Siriraj Hospital, Mahidol University)
Protocol Chair	Pierce Chow pierce.chow@duke-nus.edu.sg

AHCC 08

Hepatocellular Carcinoma Registry in Asia (INSIGHT): Insight into Real World Practice of Management of HCC in Asia-Pacific (NCT03233360)

Status

Completed recruitment of 2533 participants in December 2019.

Preliminary results presented at ASCO 2018, ILCA (2018), ASCO GI (2019), APPLE (2019), EWALT (2022) and APASL (2022).

Publication in progress

Contributing Principal Investigators and Centres

Singapore

Pierce Chow (National Cancer Centre), Dan Yock Young (National University Hospital), Brian Goh (Singapore General Hospital)

Australia

Edmund Tse (Royal Adelaide Hospital), Prof Simone Strasser (Royal Prince Alfred Hospital)

China

Li Lequn (Guangxi Medical University Cancer Center), Jiangtao Li (Second Affiliated Hospital Zhejiang University School of Medicine), Fan Jia (Zhongshan Hospital, Fudan University), Zhu Xu (Beijing Cancer Hospital), Yuxian Bai (Harbin Medical University Cancer Hospital), Qin Shu-Kui (Nanjing Bayi Hospital)

Hong Kong

Prof Thomas Yau (Queen Mary Hospital)

Japan

Masatoshi Kudo (Kindai University Hospital), Junji Furuse (Kyorin University School of Medicine), Kazuaki Shimada (National Cancer Centre), Kiyoshi Hasegawa, (University of Tokyo), Nobuyuki Takemura (National Center of Global Health and Medicine)

New Zealand

Adam Bartlett (Auckland City Hospital)

South Korea

Hyun-Ki Yoon (Asan Medical Centre), Kim Yun-Hwan (Korea University Anam Hospital), Joon-Hyeok Lee (Samsung Medical), Ho-Seong Han (Seoul National University Hospital), Yang Jin-Mo (St Vincents Hospital), Choi Jong-Young (St. Mary’s Hospital), Hee-Jung Wang (Ajou University Hospital), Do-Young Kim (Severance Hospital, Yonsei University College of Medicine)

Taiwan

Peng-Cheng Yuan (China Medical University Hospital), Yee Chao (Taipei Veterans General Hospital), Tsung-Hui Hu (KS-Chang Gung Memorial Hospital), Pin-Nan Cheng (National Cheng Kung University Hospital), Chien-Hung Chen (National Taiwan University Hospital)

Thailand

Rawisak Chanwat (National Cancer Institute), Supot Ninanong (Siriraj Hospital, Mahidol University)

Protocol Chair

Pierce Chow
pierce.chow@duke-nus.edu.sg

AHCC07

AHCC 07	Precision Medicine in Liver Cancer across an Asia-Pacific Network (The PLANet Study) (NCT03267641)
Status	Completed recruitment of 147 patients in January 2021. (planned recruitment is 100), of which 132 patients have reached the study end-point (as defined by recurrence, death or completion of 2 year follow-up from date of surgery). Two main publications in Cell (DOI: 10.1016/j.cell.2020.08.040) and Nature Communications (DOI: 10.1038/s41467-020-20171-7). Patent: A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient (Valerie Chew, Pierce Chow, Albani Salvatore) (Application number: 10201709924T; Filing Date: 30/11/2017) Cell-based biomarkers of immunotherapy in hepatocellular carcinoma (Ankur Sharma, Florent Ginhoux, Ramanuj Dasgupta, Pierce Chow) (Singapore Provisional Application number.: 10202007868Q; Filing Date: 17/08/2020)
Contributing Principal Investigators and Centres	Malaysia Yoong Boon Koon (University Malaya Medical Center) Philippines Maria Vanessa H. de Villa (The Medical City) Singapore Pierce Chow (National Cancer Centre), Glenn Bonney (National University Hospital), Brian Goh (Singapore General Hospital) Thailand Rawisak Chanwat (National Cancer Institute) United States of America Sabino Zani Jr (Duke University School of Medicine)
Thematic Principal Investigators	Theme: Genomic evolution in HCC and the discovery of novel drug targets Name: Zhai Weiwei Designation: Senior Research Scientist Institution: Genome Institute of Singapore Theme: Translational Immunomics: Immune-phenotyping, monitoring and discovery of novel immunotherapies Name: Salvatore Albani Designation: Director Institution: SingHealth Translational Immunology and Inflammation Centre Theme: Clinical Trajectory and Translational Therapeutics Name: Pierce Chow Designation: Senior Consultant Institution: National Cancer Centre
Protocol Chair	Pierce Chow pierce.chow@duke-nus.edu.sg

AHCC06

AHCC 06	Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB) (NCT01135056)
Status	Complete recruitment of 360 patients in July 2018. Results presented at ASCO Annual Meeting (2017), APPLE Meeting (2017), Evidence Based Medicine Forum for Hepato-Biliary-Pancreatic Cancer (2017) and ILCA (2017). Published in J. Clin. Oncol. (DOI: 10.1200/JCO.2017.76.0892), JMIR Res. Protoc. (DOI: 1010.2196/resprot.7016), BMC Cancer (DOI: 10.1186/s12885-016-2868-y) and Future Oncol. (DOI: 10.2217/fon-2017-0395)
Contributing Principal Investigators and Centres	Brunei Kenneth Kok (The Brunei Cancer Centre) Indonesia L.A Lesmana (Cipto Mangunkusumo Hospital, University of Indonesia), Tjakra Wibawa Manuaba (Sanglah General Hospital, Denpasar) Malaysia Aloysius Raj (Penang Adventist Hospital), Nik Azim Bin Nik Abdullah (Sarawak General Hospital), Yoong Boon Koon (University Malaya Medical Center) Mongolia Ariunaa Khasbazar (National Cancer Center of Mongolia) Myanmar Khin Maung Win (Yangon GI & Liver Centre) New Zealand Adam Bartlett (Auckland City Hospital) Philippines Rolley Lobo (Davao Doctors Hospital), Catherine Teh (Makati Medical Center), Janus Ong (The Medical City), Ian Cua (St Luke’s Medical Center) Singapore Kenneth Mak (Khoo Teck Puat Hospital), David Tai (National Cancer Centre), Dan Yock Young (National University Hospital), Cheow Peng Chung (Singapore General Hospital) South Korea Hyun-Ki Yoon (Asan Medical Center), Yun-Hwan Kim (Korea University Anam Hospital), Ho-Seong Han (Seoul National University Bundang Hospital) Si-Hyun Bae (Seoul St Mary’s Hospital), Jong Yun Won (Severance Hospital, Yonsei University), Jin-Mo Yang (St Vincent’s Hospital) Taiwan Chien-Fu Hung (Chang Gung Memorial Hospital), Chao-Long Chen (Chang Gung Memorial Hospital, Kaohsiung), Cheng-Yuan Peng (China Medical University Hospital), Po-Chin Liang (National Taiwan University Hospital), Rheun-Chuan Lee (Taipei Veterans General Hospital) Thailand Chanisa Chotipanich (Chulabhorn Hospital)
Protocol Chair	Pierce Chow pierce.chow@duke-nus.edu.sg

AHCC 06

Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB) (NCT01135056)

Status

Complete recruitment of 360 patients in July 2018.

Results presented at ASCO Annual Meeting (2017), APPLE Meeting (2017), Evidence Based Medicine Forum for Hepato-Biliary-Pancreatic Cancer (2017) and ILCA (2017).

Published in J. Clin. Oncol. (DOI: 10.1200/JCO.2017.76.0892), JMIR Res. Protoc. (DOI: 1010.2196/resprot.7016), BMC Cancer (DOI: 10.1186/s12885-016-2868-y) and Future Oncol. (DOI: 10.2217/fon-2017-0395)

Contributing Principal
Investigators and Centres

Brunei

Kenneth Kok (The Brunei Cancer Centre)

Indonesia

L.A Lesmana (Cipto Mangunkusumo Hospital, University of Indonesia), Tjakra Wibawa Manuaba (Sanglah General Hospital, Denpasar)

Malaysia

Aloysius Raj (Penang Adventist Hospital), Nik Azim Bin Nik Abdullah (Sarawak General Hospital), Yoong Boon Koon (University Malaya Medical Center)

Mongolia

Ariunaa Khasbazar (National Cancer Center of Mongolia)

Myanmar

Khin Maung Win (Yangon GI & Liver Centre)

New Zealand

Adam Bartlett (Auckland City Hospital)

Philippines

Rolley Lobo (Davao Doctors Hospital), Catherine Teh (Makati Medical Center), Janus Ong (The Medical City), Ian Cua (St Luke’s Medical Center)

Singapore

Kenneth Mak (Khoo Teck Puat Hospital), David Tai (National Cancer Centre), Dan Yock Young (National University Hospital), Cheow Peng Chung (Singapore General Hospital)

South Korea

Hyun-Ki Yoon (Asan Medical Center), Yun-Hwan Kim (Korea University Anam Hospital), Ho-Seong Han (Seoul National University Bundang Hospital) Si-Hyun Bae (Seoul St Mary’s Hospital), Jong Yun Won (Severance Hospital, Yonsei University), Jin-Mo Yang (St Vincent’s Hospital)

Taiwan

Chien-Fu Hung (Chang Gung Memorial Hospital), Chao-Long Chen (Chang Gung Memorial Hospital, Kaohsiung), Cheng-Yuan Peng (China Medical University Hospital), Po-Chin Liang (National Taiwan University Hospital), Rheun-Chuan Lee (Taipei Veterans General Hospital)

Thailand

Chanisa Chotipanich (Chulabhorn Hospital)

Protocol Chair

Pierce Chow
pierce.chow@duke-nus.edu.sg

AHCC 05

AHCC 05	Phase I/II Study of SIR-Spheres plus Sorafenib (Chemo-Radiotherapy) as First Line Treatment in Patients with Non-Resectable Primary Hepatocellular Carcinoma
Status	Completed in June 2009 with recruitment of 35 patients. Published in PLoS ONE 2014 9(3):e90909. doi: 10.1371/journal.pone.0090909.
Contributing Principal Investigators and Centres	Pierce Chow (SGH, Singapore), Anthony Goh (SGH, Singapore), Soo Khee Chee (NCC, Singapore), Tan Say Beng (SCRI, Singapore), Alexander Chung (SGH, Singapore), Lai Hee Kit (SGH, Singapore), Tay Kiang Hiong (SGH, Singapore), Richard Lo Hoau Gong (SGH, Singapore), Donald Poon Yee Hee (NCC, Singapore), Choo Su Pin (NCC, Singapore), Han Ho Seong (Seoul, Korea), Harjit Singh (Selayang, Malaysia), Khin Maung Win (Yangon, Myanmar)
Protocol Chair	Pierce Chow pierce.chow.k.h@sgh.com.sg

AHCC 04

AHCC 04	Phase II Dose Escalating Trial of Intra-Tumoral BrachySil in Unresectable Hepatocellular Carcinoma
Status	Completed. Results Published in International Journal of Radiation Oncology Biology Physics Vol. 67, Issue 3, 1 March 2007; 786-792.
Contributing Principal Investigators and Centres	Pierce Chow (SGH, Singapore), Anthony Goh (SGH, Singapore), Richard Guan (Mt Elizabeth Hospital, Singapore), Foo Kian Fong, Susan Loong (NCC, Singapore), Liau Kui Hin (TTSH, Singapore), Hoang Hoa Hai (Choray Hospital, Ho Chi Minh City), Harjit Singh (Selayang Hospital, Kuala Lumpur)
Protocol Chair	Pierce Chow pierce.chow.k.h@sgh.com.sg

AHCC 03

AHCC 03	Randomised Trial of Adjuvant Intra-Arterial Radio-Active Iodine after Curative Resection of Hepatocellular Carcinoma
Status	Completed in March 2007 with recruitment of 103 patients. Published inWorld J Surg 6 March 2013: 1-6.
Contributing Principal Investigators and Centres	Pierce Chow (SGH, Singapore), Lucien Ooi (NCC, Singapore), Tay Khoon Hean (CGH, Singapore), Chew Soo Ping (TTSH, Singapore)
Protocol Chair	London Ooi dsoopj@nccs.com.sg

AHCC 02

AHCC 02	Randomized Double Blind Trial of Megestrol Acetate Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma
Status	Completed in 2007 with recruitment of 204 patients. Results published in Br J Cancer 2011 September 27;105(7): 945–952.
Contributing Principal Investigators and Centres	Pierce Chow (SGH, Singapore), Khin Maung Win (Yangon, Myanmar), Soo Khee Chee (NCC, Singapore), Hoang Hoa Hai (Ho Chi Minh City, Vietnam), Nguyen Ba Duc (Hanoi, Vietnam), Jin Mo-Yang (Suwon, Korea), Rolley Lobo (Davao City, Philippines), M Findlay (Auckland, New Zealand)
Protocol Chair	Pierce Chow pierce.chow.k.h@sgh.com.sg

AHCC 01

AHCC 01	Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma
Status	Completed in June 2000 with recruitment of 324 patients. Results published in Hepatology 2002 36:1221-1226.
Contributing Principal Investigators and Centres	Pierce Chow (SGH, Singapore), Khin Maung Win (Yangon, Myanmar), Phillip Johnson (Shatin, Hong Kong), Soo Khee Chee (NCC, Singapore), Tan Chee Kiat (Singapore), T Manuaba (Denpasar, Indonesia), Thiravud Khuhaprema (Thailand), A Haron (Bangi, Malaysia), Si-Hyun Bae (Korea), J Cebon (Australia), M Findlay (Wellington, New Zealand)
Protocol Chair	Pierce Chow pierce.chow.k.h@sgh.com.sg